University of Arizona researchers have revealed new insights into one of the most common complications faced by Parkinson’s disease patients: uncontrollable movements that develop after years of treatment.
In drug development, diversity must be extended to preclinical research
The pharmaceutical industry has long operated on a one-size-fits-all model, developing drugs primarily tested on, and thus best suited for, people of European descent. This
August 22, 2024